pharma · Duchenne muscular dystrophy (DMD) · JAK2V617F-positive high-risk Polycythemia Vera
ITALFARMACO S.P.A
Italfarmaco S.p.A.
Italfarmaco S.p.A is a pharma organization headquartered in MILANO, IT. Primary therapeutic focus areas include Duchenne muscular dystrophy (DMD), JAK2V617F-positive high-risk Polycythemia Vera, Chronic myeloproliferativ
Cinisello Balsamo, IT HQ
1938 Founded
629 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Cinisello Balsamo, IT
- Founded
- 1938
- Employees
- 629
- Programs
- 7
- Drugs
- 17
- Patents
- 0
DSC/14/2357/50
Phase 3 · small molecule · Duchenne muscular dystrophy (DMD)
DSC/14/2357/50 for Duchenne muscular dystrophy (DMD) is a Phase 3 program (small_molecule) at Italfarmaco S.p.A. with 1 ClinicalTrials.gov record(s).
Internal code DSC/14/2357/50
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Italfarmaco S.p.A.
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Duchenne muscular dystrophy (DMD)
- Status
- active
- Trials
- 1